Johnson & Johnson Pharmaceutical Research & Development, LLC (CA) Scientists Uncover Previously Unknown Role for Class of Molecules
8/4/2011 2:52:19 PM
More...
|
Johnson & Johnson Pharmaceutical Research & Development, LLC (CA): In Study of Acutely Ill Patients Rivaroxaban Compares Favorably With Enoxaparin in Preventing Venous Thromboembolism but With an Increased Rate of Bleeding
4/5/2011 8:43:59 AM
More...
|
Isogenica Limited Announces Collaboration with Johnson & Johnson Pharmaceutical Research & Development, LLC (CA)
3/22/2011 10:37:52 AM
More...
|
Johnson & Johnson Pharmaceutical Research & Development, LLC (CA) Release: Rivaroxaban Successfully Demonstrated Non-Inferiority Compared to Standard of Care for the Prevention of Recurrent Venous Thromboembolism in Pivotal Phase 3 Study
8/31/2010 10:07:02 AM
More...
|
New Johnson & Johnson Pharmaceutical Research & Development, LLC (CA) Diabetes Drug, Canagliflozin Effective in Mid-Stage Study
6/28/2010 6:38:09 AM
More...
|
WuXi PharmaTech Co., Ltd. Enters into Collaboration with Johnson & Johnson Pharmaceutical Research & Development, LLC (CA), a division of Janssen Pharmaceutica for Preclinical Services and Training
3/2/2010 8:43:07 AM
More...
|
FDA Approves Johnson & Johnson Pharmaceutical Research & Development, LLC (CA)'s (JOBS) INVEGA(R) SUSTENNA(TM) for the Acute and Maintenance Treatment of Schizophrenia
8/3/2009 7:45:20 AM
More...
|
PPD, Inc. (PPDI) Confirms Johnson & Johnson Pharmaceutical Research & Development, LLC (CA)'s (JOBS) Completion of Additional Phase III Studies Providing Expanded Safety and Efficacy Data for Priligy
6/10/2009 7:07:24 AM
More...
|
Johnson & Johnson Pharmaceutical Research & Development, LLC (CA) Release: Three Clinical Presentations on Tapentadol Extended Release Tablets for Chronic Pain
5/7/2009 12:10:39 PM
More...
|
Johnson & Johnson Pharmaceutical Research & Development, LLC (CA) Announces FDA Filings for Paliperidone Palmitate and INVEGA(R)
2/6/2009 8:31:36 AM
More...
|
|